Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Adaptive Biotechnologies (NASDAQ:ADPT) had its price target boosted by stock analysts at Morgan Stanley from $20.00 to $22.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would indicate a potential downside of 5.07% from the stock’s previous close.

ADPT has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. JPMorgan Chase & Co. reduced their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. TD Cowen increased their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Thursday. Guggenheim upped their price target on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday. Finally, BTIG Research boosted their price objective on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.

Adaptive Biotechnologies Price Performance

Shares of ADPT traded up $0.61 on Thursday, hitting $23.17. The company’s stock had a trading volume of 2,384,537 shares, compared to its average volume of 2,314,949. Adaptive Biotechnologies has a fifty-two week low of $9.96 and a fifty-two week high of $23.88. The company has a 50 day moving average price of $19.05 and a 200 day moving average price of $16.56. The company has a market capitalization of $3.71 billion, a PE ratio of -69.89 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. During the same period in the prior year, the business posted ($0.20) EPS. The company’s quarterly revenue was up 35.1% on a year-over-year basis. On average, equities analysts forecast that Adaptive Biotechnologies will post -0.47 EPS for the current year.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 492,400 shares of the company’s stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the completion of the transaction, the insider directly owned 812,058 shares in the company, valued at approximately $17,775,949.62. This represents a 37.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 11,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $18.00, for a total value of $198,000.00. Following the completion of the sale, the insider directly owned 416,775 shares of the company’s stock, valued at approximately $7,501,950. This trade represents a 2.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,305,787 shares of company stock worth $27,828,563. 5.70% of the stock is currently owned by company insiders.

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Westfield Capital Management Co. LP acquired a new stake in Adaptive Biotechnologies in the fourth quarter worth about $65,942,000. Price T Rowe Associates Inc. MD boosted its holdings in Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares during the period. Invesco Ltd. boosted its stake in shares of Adaptive Biotechnologies by 248.8% during the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after acquiring an additional 2,216,595 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Adaptive Biotechnologies by 544.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after buying an additional 2,062,282 shares during the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Analysts raised price targets: TD Cowen increased its target from $25 to $28 and assigned a “buy” rating, implying approximately 21.8% upside from the cited price. BTIG Research also raised its target from $24 to $25 and reiterated a “buy” rating. These revisions reinforce the bullish view following the quarterly update. Benzinga analyst price-target reports
• Positive Sentiment: Revenue exceeded expectations in the second quarter: Adaptive reported approximately $71.6 million in revenue, above the roughly $65.4 million analyst estimate, with year-over-year growth of 21.5%. Zacks also reported a quarterly loss of $0.10 per share versus an expected loss of $0.13, and the loss improved from $0.17 per share a year earlier. Adaptive Biotechnologies second-quarter financial results
• Positive Sentiment: Brokerage sentiment remains favorable: The stock carries a consensus “Moderate Buy” rating, with five analysts rated Buy, one Hold and one Sell. The latest target increases improve the potential upside relative to the prior consensus. Adaptive Biotechnologies brokerage ratings
• Neutral Sentiment: Second-quarter results were mixed depending on the metric: While revenue beat estimates, one report showed EPS of negative $0.25, missing the consensus estimate of negative $0.13. The earnings call transcript may provide additional details on operating performance and forward guidance. Adaptive Biotechnologies second-quarter earnings call transcript
• Negative Sentiment: Insider selling adds a potential cautionary signal: Director Harlan Robins sold 492,400 shares worth approximately $10.8 million, reducing his position by 37.75%. However, the transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which reduces its significance as a discretionary bearish signal. Adaptive Biotechnologies insider sale

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.